Page 2 - சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் Today - Breaking & Trending Today

NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy

2
indication approved for Toripalimab in China
SHANGHAI, China, Feb. 22, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. This is the first approval of immune checkpoint blockade therapy in NPC in the world and the second approved indication for toripalimab in China. In December 2018, Toripalimab obtained a conditional approval from the NMPA for the second-line treatment of unresectable or metastatic melanoma. ....

United States , San Francisco , Ruihua Xu , Patricia Keegan , Junshi Biosciences , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Guidelines Of Chinese Society Clinical Oncology , Ir Team , World Health Organization , Drug Administration , Sun Yat Sen University Cancer Center , National Reimbursement Drug List , National Medical Products Administration , Pr Team , Sun Yat Sen University Cancer , Chief Medical Officer , For Global , Chinese Society , Clinical Oncology , Breakthrough Therapy Designation , National Reimbursement Drug , Drug Designations , Microbiology Chinese Academy , Emergency Use Authorization , ஒன்றுபட்டது மாநிலங்களில் ,

Junshi Biosciences: NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy

Junshi Biosciences: NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Ruihua Xu , Patricia Keegan , Junshi Biosciences , Guidelines Of Chinese Society Clinical Oncology , Ir Team , World Health Organization , Drug Administration , Sun Yat Sen University Cancer Center , National Reimbursement Drug List , National Medical Products Administration , Pr Team , Sun Yat Sen University Cancer , Chief Medical Officer , For Global , Chinese Society , Clinical Oncology , Breakthrough Therapy Designation , National Reimbursement Drug , Drug Designations , ஒன்றுபட்டது மாநிலங்களில் , பாட்ரிசியா கீகந் , வழிகாட்டுதல்கள் ஆஃப் சீன சமூகம் மருத்துவ புற்றுநோயியல் , ஈர் அணி , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் ,

Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma

(2)
the 3rd sNDA for Toripalimab in China
SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for Toripalimab combined with chemotherapy for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.
The supplemental NDA is based on the JUPITER-02 study (NCT03581786), which is a randomized, double-blind, placebo-controlled Phase III study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The results of the study showed that Toripalimab combined with gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma significantly prolonged the progressio ....

United States , Ruihua Xu , Junshi Biosciences , Guidelines Of Chinese Society Clinical Oncology , Ir Team , World Health Organization , Drug Administration , Sun Yat Sen University Cancer Center , National Reimbursement Drug List , National Medical Products Administration , Pr Team , New Drug Application , Sun Yat Sen University Cancer , Breakthrough Therapy , Orphan Drug Designations , Biologics License Applications , Chinese Society , Clinical Oncology , New Drug Applications , Breakthrough Therapy Designation , Toripalimab Injection , Drug Designations , ஒன்றுபட்டது மாநிலங்களில் , வழிகாட்டுதல்கள் ஆஃப் சீன சமூகம் மருத்துவ புற்றுநோயியல் , ஈர் அணி , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,

Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma | Comunicados | Edición USA

the 3rd sNDA for Toripalimab in China
SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for Toripalimab combined with chemotherapy for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.
The supplemental NDA is based on the JUPITER-02 study (NCT03581786), which is a randomized, double-blind, placebo-controlled Phase III study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The results of the study showed that Toripalimab combined with gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma significantly prolonged the progression-free s ....

United States , San Francisco , Ruihua Xu , Junshi Biosciences , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Guidelines Of Chinese Society Clinical Oncology , Ir Team , World Health Organization , Drug Administration , Sun Yat Sen University Cancer Center , National Reimbursement Drug List , National Medical Products Administration , Pr Team , Junshi Biosciences Announces Acceptance , Supplemental New Drug Application , Toripalimab Combined , First Line Treatment , New Drug Application , Sun Yat Sen University Cancer , Breakthrough Therapy , Orphan Drug Designations , Biologics License Applications , Chinese Society , Clinical Oncology , New Drug Applications ,

Deep learning helps predicting occult peritoneal metastasis in stomach cancer

E-Mail
IMAGE: Example of one CT image and the corresponding output from the deep learning model
view more
Credit: SIAT
Stomach cancer, or gastric cancer, is a common gastrointestinal malignancy. Peritoneal metastasis occurs in a majority of patients with advanced stomach cancer and is considered as an aggressive disease with poor outcomes.
Patients with peritoneal metastasis are typically not eligible for curative surgery. Therefore, preoperative detection and diagnosis of peritoneal metastasis are critical to inform treatment decision-making and avoid unnecessary surgery.
A new study published in the
JAMA Network Open on Jan. 5 shows that deep learning can help predicting the occult peritoneal metastasis in stomach cancer. It provides a novel and noninvasive approach for stomach cancer patients and may inform individualized surgical management of stomach cancer. ....

Peritoneal Metastasis Network Pmetnet , Network Open On Jan , Shenzhen Institutes Of Advanced Technology , Stanford University , Chinese Academy Of Sciences , Sun Yat Sen University Cancer Center , Shenzhen Institutes , Advanced Technology , Chinese Academy , Nanfang Hospital , Sun Yat Sen University Cancer , Peritoneal Metastasis Network , வலைப்பின்னல் திறந்த ஆன் ஜான் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , சீன கலைக்கழகம் ஆஃப் அறிவியல் , சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் , ஷென்சென் நிறுவனங்கள் , சீன கலைக்கழகம் , சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் ,